8 mar 2024 año - Wegovy Approved by The FDA
Descripción:
The FDA expands the approval of semaglutide (Wegovy) to include heart disease, making it the first weight-loss drug to be approved for reducing the risk of cardiovascular events in adults who have cardiovascular disease and are either obese or overweight.
Añadido al timeline:
fecha:
8 mar 2024 año
Ahora mismo
~ 1 years and 3 months ago